Skip to main content
SBFM logo

SBFM · Sunshine Biopharma Inc.

$1.67 -0.04 (-2.34%) At close · Jul 24
Market Cap
$8.31M
Shares
5.01M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.71 Open$1.77 Day$1.70–1.79 52W$1.70–24.30 Avg vol 30d97K Short int62K · 1.2% float · 1.3d Short vol17% DataFeb 2022–Jul 2026 Filing10-Q · May 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.6 · elevated Equity put/call 0.79
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −84%
below
Price vs 50-day avg −39%
below
RSI (14) 30
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −86%
trailing
YTD return −86%
this year
Relative strength −93%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $11 — 200d above 50d
Institutional flow Distributing
3 of 12 funds reported for Jun 30 · net -21 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.25% of float · ▼ -45.0% MoM · 1.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
12 holders — mid 1-yr range
Squeeze score 31
low risk · 0–100
Fundamentals
Strong
Revenue growth +4%
Y/Y
Gross margin 34%
expanding
EPS growth +98%
Y/Y
Free cash flow $-5.5M
Buyback $2.0M
authorized
Balance sheet $20.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 129%
annualized · 1-yr
Max drawdown −92%
past year
ATR 13.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−84% Bearish
Price vs 50-day avg
−39% Bearish
RSI (14)
30 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $3 › 200d $11 — 200d above 50d
Institutional flow Distributing
3 of 12 funds reported for Jun 30 · net -21 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.25% of float · ▼ -45.0% MoM · 1.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
12 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $2 Now $2 · 0% 52-wk high $24
vs 200-day avg -84% vs 50-day avg -39%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SBFM
Sunshine Biopharma Inc.
this stock
$8.31M -86.1% +4.1% 1.2%
TAK
Takeda Pharmaceutical Co Ltd
$55.06B +10.6% 0.1%
GALDY
Galderma Group AG/ADR
$49.54B +2.5% 0.0%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
$45.13B 0.0%
HLN
Haleon plc
$43.07B -4.0% 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
11
% held
0.2%
Reported
3 of 12
Top holder
CITADEL ADVISORS LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
62.5K
Days to cover
1.3d
Change
-51.0K sh
View
Short Volume
Short vol %
17%
As of
Jul 24, 2026
Short Total
View
Fails to Deliver
FTD shares
1.4K
Value
$2.9K
As of
Jun 26, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Roger Williams
Amount
$1.0K–$15.0K
Traded
Jun 30, 2022
View
Financials
Financials
Revenue (FY)
$36.3M
Net income (FY)
$-6.0M
EPS diluted
$-73.20
View
Buybacks
Authorized
$2.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 20, 2026
This year
10
View
Exempt Offerings
Offering
$5.0M
Filed
May 17, 2023
View

Performance

5D 20D 120D MTD YTD
SBFM -6.6% -16.2% -86.2% -18.6% -86.1%
SPY -1.7% +0.7% +6.4% -1.2% +8.3%
vs SPY -4.9% -16.9% -92.6% -17.4% -94.4%

Capital returns

Buyback program · as of Jan 19, 2023
Authorized
$2.00M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1402328 CUSIP 867781809 13F (30d) 3 filings 3 filers Visit website Investor relations